Table 1.

Baseline characteristics at the time of liver transplantation

	mTOR inhibitor (n = 79)	No mTOR inhibitor (n = 64)	P value
Age at transplant (years)	57 (50-62)	53 (46-59)	0.07
Gender (%M)	75 (95%)	57 (89%)	0.19
Etiology			0.28
Cryptogenic	1 (1%)	4 (6%)
HBV	72 (91%)	59 (92%)
HCV	4 (5%)	1 (2%)
Alcoholic liver disease	3 (4%)	2 (3%)
Primary/salvage transplant	49/30	43/21	0.52
Cadaveric/living related	53/26	47/17	0.41
Whole graft/partial graft	53/26	47/17	0.41
No. of tumours	2 (1-5)	2 (1-6)	0.85
Size of largest tumour (cm)	4.3 (2.9-6.6)	4.0 (2.5-6.5)	0.68
AFP (ng/mL)	144 (14-1388)	111 (19-817)	0.51
Within Milan criteria	21 (27%)	14 (22%)	0.54
Within UCSF criteria	26 (33%)	15 (23%)	0.22

AFP: Alpha-fetoprotein; HBV: Hepatitis B virus; HCV: Hepatitis C virus; mTOR: Mammalian target of rapamycin.